The efficacy of anthracycline-and taxane-based chemotherapy for perioperative treatment of breast cancer (BC) has been established. No superiority of a cytotoxic regimen has been demonstrated, provided that administration of an anthracycline and a taxane is warranted. The ASTER study was designed to investigate the safety Twenty-eight (8.5%) developed grade III-IV hematologic toxicity; nine patients (2.7%) developed grade III neurological toxicity. Loco-regional DFS was 99.6% at 1 year, 97.1% at 5 years, 95.9% at 7 years. Corresponding distant DFS was 98.4%, 90.2%, and 88.8%. One, 5, and 7-year OS was 99.6%, 94.9%, and 91.2%, respectively. Chemotherapy with ATx3→CMFx3 is confirmed safe and effective at 6.7 years followup. These results appear comparable to those reported in regulatory trials of most commonly prescribed anthracycline and taxane-based regimens.
| INTRODUCTION
The role of adjuvant chemotherapy for early stage breast cancer (BC) has been established. 1 At first, 12 cycles of CMF* proved efficacy in prolonging survival after surgery in patients with axillary metastases. 2 Then, the introduction of anthracyclines led to the development of new therapeutic regimens such as FAC †, FEC ‡, EC §, and AC**. 3 In the 1990s, taxanes were introduced in clinical practice, leading to more complex drug sequences and combinations. Indeed, the therapeutic arsenal could be enriched by regimens such as AC→T † †, TAC ‡ ‡, FEC→D § §, and TC***, which improved survival against previous standards. 4 -7 A parallel branch of research focused on neo-adjuvant setting. At first this strategy was considered suitable for locally advanced inoperable cases, but was then extended to early cases in order to allow conservative surgery. 8 The same regimens used in adjuvant setting were proved effective with this intent and no differences in long-term outcome were seen between neoadjuvant and adjuvant treatments. 9, 10 With the progressive survival prolongation, more and more attention was paid to toxicity concerns. 11 Given the known relation between paclitaxel cumulative dose and incidence of toxicity, in particular the neurologic one, we hypothesized that a reduced treatment duration may diminish moderate and severe neurologic adverse events (AEs). 12 Previous studies tested different durations of chemotherapy, without finding a benefit when the treatment was extended beyond 4 months. 13 Moreover, no differences in efficacy could be evidenced between cytotoxic regimens, provided that a sequence or a combination of anthracyclines and taxanes was granted. 3 On these bases we designed a study evaluating the incidence of toxicity in patients treated with AT † † †x3→CMFx3. This study was named ASTER (Adjuvant Safety Taxol Event Related) and was a phase II single-arm safety trial. The regimen chosen was developed based on the previous results of European Cooperative Trial in Operable Breast Cancer (ECTO). This phase III study evaluated the addition of Paclitaxel to Doxorubicin followed by CMF, as adjuvant or primary systemic therapy. The study had shown a better performance of AT→CMF vs Doxorubicin alone followed by CMF, with acceptable toxicity, and without differences between neo-adjuvant and adjuvant setting. 14, 15 Herein, we present the results of ASTER study after a median follow-up of 6.7 years.
| MATERIALS AND METHODS

| Study design and inclusion/exclusion criteria
The ASTER study was a phase II single-arm safety trial. Its primary objective consisted of evaluating whether an inferior cumulative dose of Paclitaxel was associated with a reduced incidence of neurologic toxicity graded ≥2 according to Common Terminology Criteria for AEs (CTCAE) version 3.0. 16 Its secondary objective was to report any toxicities related to study treatment. Although efficacy was not a predefined outcome, data about disease-free and overall survival (DFS and OS, respectively) of the trial population were analyzed.
Women aged 18-70 years old were eligible for inclusion in the study when presenting a histological diagnosis of invasive BC, staged cT2- 
| Protocol treatment
The patients received Doxorubicin 60 mg/sm iv bolus d1 q21 and
Paclitaxel 200 mg/sm iv through 3 hours of infusion d1 q21 for three cycles followed by Cyclophosphamide 600 mg/sm iv bolus d1,8 q28, 
| Study procedures and follow-up
Screening procedures required anamnesis and physical examination, Evaluation of AEs was repeated before each cycle. Anamnesis and neurological examination was regularly performed during therapy, then at least once a year. Assessment of the left ventricular ejection fraction (LVEF) had the same schedule for the whole study period.
The patients were followed-up after the end of treatment with physical examination, hematological, and biochemistry evaluations every 6 months for 5 years; and breast x-ray and ultrasound, chest x-ray, abdomen ultrasound, and bone scan once a year for 5 years.
| Loco-regional treatment
After the conclusion of neo-adjuvant chemotherapy or in case of progression during preoperative treatment, the patients underwent breast surgery within 4 weeks. A conservative approach was preferred, whenever feasible and according to the patients' preference. Sentinel lymph node biopsy was performed in cases staged cN0 at the initial evaluation. The patients treated with conservative surgery were candidates for complimentary radiation therapy, which was started within 6 weeks after the surgical intervention, or at the conclusion of chemotherapy in cases treated in an adjuvant setting.
Radiotherapy was administered with standard fractioning, up to a final dose of 60 Gy (50 Gy on whole breast +10 Gy boost on tumor bed). Patients treated with radical surgery received radiation therapy in locally advanced cases only.
| Toxicity and efficacy evaluations
Safety data were descriptively analyzed in all patients who received at least one full dose of study medication. Data about neurologic toxicity were mainly compared with those reported in National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28. 6 A comparative assessment was also done with ECTO trial. (RECIST) version 1.1. 17 We defined pathologic complete response (pCR) as the absence of infiltrating tumor in both breast and lymph node. The presence of in situ lesions was therefore considered as a pCR. 18 Progressive disease, inacceptable toxicity, and insurgence of other serious conditions constituting a risk for treatment continuation and/or surgery were considered criteria for early discontinuation of the study.
| Statistical evaluation
Progression-free survival (PFS) was defined as the time interval between surgery, and relapse or follow-up. OS was defined as the time interval between surgery, and death or follow-up. PFS and OS were estimated by Kaplan-Meier method. Comparisons of survival curves between different groups were analyzed with log-rank test.
The significance level was set at 0.05. Statistical analyses were performed with GraphPad Prism version 5.02. 
| RESULTS
| Patient characteristics
| Efficacy results
Median follow-up was 6.7 years (range: 0.2-8.9). In the overall population, neither loco-regional nor distant median DFS was reached. Loco- (Figure 1 ).
| Toxicity results
The treatment was well-tolerated. In particular, 299 patients (90.6%)
did not have hematologic toxicities, 203 (61.5%) did not experience neurologic AEs. Grade III or IV hematologic toxicities occurred in only 28 patients (8.5%). As regards neurologic toxicity, nine (2.7%) grade III neurologic AEs were registered. Other relevant (ie, graded ≥2) AEs included four cases of severe mucositis, one grade III aminotransferase elevation, and one case of allergic reaction to paclitaxel.
No cases of moderate to severe cardiac toxicity were reported, as well as long-term or delayed AEs. Toxicity data, with a comparison with the historical cohorts of NSABP B-28 for neurologic AEs and ECTO for the other AEs, are detailed in Table 2 .
| CONCLUSION
With the limitations related to a retrospective parallel and a different cumulative dose of taxanes administered, ASTER regimen appears to be associated with a reduced incidence of neurologic AEs in comparison to NSABP B-28 one. In fact, NSABP B-28 registered severe neurotoxicity in 18.0% of patients, while only nine patients (2.7%) developed this AE in ASTER. 6 Notably, the incidence of neurologic toxicity with ASTER regimen appears also lower to that reported in ECTO, whose dose of paclitaxel per cycle was the same of ASTER trial. In fact, grade II neuropathy was recorded in 27.5% of ECTO patients, but only in 6.1% of ASTER patients. 15 Again with the limitations of a comparison with a historical cohort, these observations seem to confirm that a short-course chemotherapy is able to limit the incidence of a potentially invalidating toxicity.
The AEs different from the neurologic ones showed a modest reduction, in comparison with the historical cohort of NSABP B-28. 6 In particular, grade ≥3 hematologic toxicity decreased from 9.4% to 8.5% and mucositis from 6.7% to 2.9%. This observation is consistent with a reduced exposure to anthracyclines and taxanes.
Although such AEs have an acute onset and generally do not entail long-term sequelae, they can limit patients' quality of life during chemotherapy and be life threatening in severe cases. Indeed, the reduced incidence of early-onset AE is a comparably desirable result of short-course treatment, potentially implementing patients' compliance.
Another important observation can be done as regards cardiac toxicity. ECTO trial reported grade ≥2 decrease in LVEF in 16.2% of patients, while no cases of grade ≥3 cardiotoxicity were registered in ASTER. 14, 15 It has to be underlined that 18.6% of the study population was also treated with neo-adjuvant or adjuvant Trastuzumab, without apparent worsening of safety profile.
Efficacy results can also be evaluated through retrospective comparison with data from ECTO. Seven-year DFS was 76.0% and 72.0% in adjuvant and neo-adjuvant treatment arms of ECTO, respectively. Corresponding OS was 85% and 84%. 14,15 ASTER documented a 5-year DFS of 92.2% and 78.9% in a post-and preoperative setting, respectively. Corresponding OS was 94.9% and 95.8%.
Again, it has to be underlined that the retrospective nature of this parallel does not allow to draw conclusions about the relative efficacy of the two experimental regimens. However, outcome data seem to suggest that a short-course chemotherapy is at least as effective as the standard regimen.
Notably, efficacy results were confirmed in ASTER triple negative subpopulation, whose median PFS and OS were not reached. Indeed, short-course chemotherapy does not seem to increase the risk of relapse or death even in the group of patients with the worst prognosis. Such an observation has to be weighed in relation to the existence of multiple neo-adjuvant and adjuvant regimens already approved for breast cancer, with comparable efficacy and similar or even shorter duration. Nonetheless, we believe that a place may be deserved for ASTER regimen among potential first choices in this setting, for different reasons. First of all, this regimen allows to administer a standard dose of Doxorubicin and Paclitaxel with a convenient and easily manageable schedule, already proven feasible in more than 97% of patients. Secondarily, the following part of the regimen is based on CMF, which is a three-drug pioneer treatment for breast cancer, with an extremely broad diffusion, a well-known and safe toxicity profile, and a low economic expensiveness.
Finally, we are well aware that no definitive conclusions are possible, due to the nonrandomized phase II nature of the trial. However, the above discussed evidences seem to suggest an advantage in prescribing a short-term chemotherapy to patients with operable BC. The particular regimen studied in ASTER seems to be sufficiently safe and effective to be proposed for use in clinical practice. Large randomized trials are needed to confirm this point and to establish the potential superiority of a specific drug combination over the others.
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E N D N O T E S
* (Cyclophosphamide 600 mg/sm iv +Methotrexate 40 mg/sm iv +Fluo-rouracil 600 mg/sm iv d1,8 q28)x6 † (Fluorouracil 600 mg/sm iv +Doxorubicin 60 mg/sm +Cyclophos-phamide 600 mg/sm iv d1 q21)x6 ‡ (Fluorouracil 600 mg/sm iv +Epirubicin 75 mg/sm +Cyclophosphamide 600 mg/sm iv d1 q21)x6 § (Epirubicin 90 mg/sm iv +Cyclophosphamide 600 mg/sm iv d1 q21)x4 ** (Doxorubicin 75 mg/sm +Cyclophosphamide 600 mg/sm iv d1 q21)x4 † † (Doxorubicin 75 mg/sm +Cyclophosphamide 600 mg/sm iv d1 q21 x 4 cycles ! Docetaxel 100 mg/sm iv d1 q21)x4 ‡ ‡ (Docetaxel 75 mg/sm iv +Doxorubicin 50 mg/sm iv +Cyclophos-phamide 500 mg/sm iv d1 q21)x6 § § (Fluorouracil 500 mg/sm iv +Epirubicin 100 mg/sm +Cyclophos-phamide 500 mg/sm iv d1 q21)x3! (Docetaxel 100 mg/sm iv d1 q21) x3 *** (Docetaxel 75 mg/sm iv +Cyclophosphamide 600 mg/sm ivd1 q21)x4 † † † (Doxorubicin 60 mg/sm iv +Paclitaxel 200 mg/sm iv d1 q21)x 3-4
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